Oncoinvent Asa · OSL:ONCIN
Oncoinvent Asa — Q1 2026 Earnings Presentation
12 slides from Oncoinvent Asa's earnings presentation, Apr 29, 2026
Slide 1: Oncoinvent: First quarter business update
Oncoinvent Transforming cancer care through direct alpha therapy First quarter business update 29 April 2026
Slide 2: Disclaimer and important information
Disclaimer and important information This presentation (the “Presentation”) has been prepared by Oncoinvent ASA (the “Company”) for information purposes only and does not constitute, and should not be construed as, an offer to sell, or a solicitation of an offer to buy, any securities of the Company
Slide 3: Oncoinvent: aiming to transform cancer care through direct alpha therapy
Oncoinvent: aiming to transform cancer care for patients through direct alpha therapy Cancer in the abdominal cavity is an area with high unmet need and few good treatment options
Slide 4: Oncoinvent: aiming to transform cancer care through direct alpha therapy
Oncoinvent: aiming to transform cancer care for patients through direct alpha therapy Cancer in the abdominal cavity is an area with Oncoinvent develops Radspherin®, a receptor- high unmet need and few good treatment independent alpha radiopharmaceutical that options eradicates cancer cells in the a
Slide 5: Ongoing clinical development
Ongoing clinical development 1H25 2H25 1H26 2H26 1H27 2H27 1H28 2H28 Ovarian Ph 1/2a Final Colorectal Final Ph 2 Ovarian N = ~110 Interim Interim Interim Final Completed Upcoming milestones 5
Slide 6: Recent Highlights
Recent Highlights o Recruited and randomized a total of 37 patients (accumulated, ITT*) into the ovarian Phase 2 trial o Secured new patent expanding protection for Radspherin® Radspherin® o Published positive final data from Phase 1 trial of Radspherin® to treat ovarian cancer – Journal: Gynecologi
Slide 7: Good recruitment momentum so far in 2026
Good recruitment momentum so far in 2026 Progress so far The way ahead o A total of 37 patients per ‘intention o Additional hospitals will be added to treat’ have been recruited and randomized by end March o Selected protocol amendments are all approved and starting to o Best quarter to date: Good s
Slide 8: Recruitment momentum is picking up
Recruitment momentum is picking up 11 Key facts: 8 7 • Q1 2026 best month so far in terms of patients recruited 4 • At current pace, Q2 trending well 1 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Six initial safety patients were included prior to randomization
Slide 9: Guiding on cash
Guiding on cash Cash position As of March 31, 2026, cash and cash equivalents totaled approximately NOK 130 million Based on the current operating plan and anticipated expenditures, Cash runway Oncoinvent continues to expect that its existing cash resources will be sufficient to fund operations into
Slide 10: Why I joined Oncoinvent
Why | joined Oncoinvent Once invent
Slide 11: Why I joined Oncoinvent
Why I joined Oncoinvent Patient need I know… ...a product rationale I believe in …a place where I can add value > > • Medical and Surgical • Radspherin® is designed to • Mission-driven team Oncology background address a clear clinical failure addressing a serious made the impact of point: microscopi
Slide 12: Financial Calendar
Financial Calendar Today Q1 update and presentation 20 May Annual General Meeting 27 August H1 report and presentation 28 October Q3 update and presentation 12